Tegoprazan and Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment
Launched by MARIO STEFFANUS · Mar 19, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Peptic ulcer disease (PUD) is a condition characterized by disruption of the gastric and duodenal mucosal lining due to exposure to gastric acid or pepsin. Major causes include Helicobacter pylori infection, nonsteroidal anti-inflammatory drug (NSAID) use, gastric bypass surgery, lifestyle factors such as smoking and alcohol consumption, and genetic predisposition. PUD affects 5-10% of the global population and poses a significant healthcare burden, with prevalence rising from 6.43 million to 8.09 million cases between 1990 and 2019.
Current PUD treatment involves acid-suppressing agents a...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects diagnosed with upper gastrointestinal bleeding caused by peptic ulcer through gastroscopic examination
- Exclusion Criteria:
- • Allergic to Tegoprazan or Lansoprazole, diagnosed with gastric or duodenal cancer, pregnant, history of H. pylori infection treatment failure, presence of comorbidities such as chronic kidney disease or decompensated liver cirrhosis, alcohol consumption, or undergoing chemotherapy.
About Mario Steffanus
Mario Steffanus is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on enhancing patient outcomes, the organization specializes in the design and management of clinical trials across various therapeutic areas. Leveraging a robust network of experienced researchers and cutting-edge technologies, Mario Steffanus aims to streamline trial processes, ensuring compliance with regulatory standards while prioritizing participant safety and ethical considerations. The sponsor's mission is to facilitate the development of breakthrough therapies that address unmet medical needs, ultimately contributing to the betterment of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jakarta, Dki Jakarta, Indonesia
Jakarta, Dki Jakarta, Indonesia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported